Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.
about
Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveysA genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300Current status and future prospects for biologic treatments of psoriasis.Development of an Inflammatory Bowel Disease Research Registry Derived from Observational Electronic Health Record Data for Comprehensive Clinical Phenotyping.A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update.A systematic review of economic studies on biological agents used to treat Crohn's disease.Mechanism and therapeutic strategy of secondary failure to anti-tumor necrosis factor-α monoclonal antibody treatment for Crohn's disease.Infectious and malignant complications of TNF inhibitor therapy in IBD.Future directions in inflammatory bowel disease management.Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?Asia-Pacific consensus statements on Crohn's disease. Part 2: Management.Development of a conceptual model evaluating the humanistic and economic burden of Crohn's disease: implications for patient-reported outcomes measurement and economic evaluation.Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.Biologic agents for IBD: practical insights.Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease.Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis.Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.Dose escalation of biologics in Crohn's disease: critical review of observational studies.Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.Letter: dry blood spots for anti-TNF treatment monitoring in IBD--authors' reply.Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis.Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease.Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study
P2860
Q26862821-6694A812-4931-403D-8616-A13EB32B024FQ28943442-FE7EFAE0-BE76-4882-A4D4-BDE922864FD6Q36057909-3F9BA1D7-ED9A-45F8-802B-00FC6A20EA87Q36130473-573B014D-8AC7-447D-BDC6-01F6B46F99AEQ37672058-0162788B-65B2-4F4A-B775-552869EF83EFQ38068963-BE757D74-D7E8-4A79-9F60-BC3B0F5DA8CAQ38116341-726729BC-8A1F-4514-8D07-A8DB5C7A7669Q38116746-37AD9B78-6BF3-4287-AC9F-89E523CD0ED6Q38138343-48FA6B36-99BC-4271-B8CF-1B2563274D83Q38205305-DA1477CF-FCE8-4A35-B9E8-89B5883EA80CQ38337716-BDE968EE-2C29-4249-8C87-CA9AB3F90DCAQ38394726-3EF5C649-2528-48AF-8A04-9E19AB4979D2Q38488635-DC985506-0FB2-4D20-8559-1CA01AA4F16EQ38549995-0B8FCD05-2465-4135-AEEF-E08EE54D0E57Q38568898-EBBB1698-B56A-4A85-B116-D1C283DA6E54Q38610162-483F1C12-1E5C-478B-B3A6-DA85392C5509Q38619950-B8437B7D-8BE6-4CA9-86BE-A8ABA8A55F24Q38950429-C5F86D44-2EBF-4F5A-939B-F2187B1ACE64Q39030608-24D1DBC5-6B9A-458A-B73B-83EB85C71F8DQ39152159-B8595B25-19B8-4ECD-B8A8-E64ACFDA95C1Q39326057-8638797B-E130-4B2D-9385-BB2009EE08E5Q39359495-B71AEF02-15D0-4AAA-860C-0CC615D6A8FBQ43986865-C8545F27-773A-415C-A9FB-826E6E8F3810Q44166494-7CDE8B6D-8D41-41B9-B960-854471FCFF74Q47862084-F7AB7473-390D-4A62-A517-26CC1654128EQ51138123-94DD238A-C83D-4056-B0E9-FBC57C30CFF4Q52844170-61B50DEA-618D-43F7-A0C0-12A57039D79CQ59120257-BC863FCD-2416-4E31-9079-1CFB92E78713
P2860
Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Long-term durability of inflix ...... " in patients losing response.
@en
Long-term durability of inflix ...... " in patients losing response.
@nl
type
label
Long-term durability of inflix ...... " in patients losing response.
@en
Long-term durability of inflix ...... " in patients losing response.
@nl
prefLabel
Long-term durability of inflix ...... " in patients losing response.
@en
Long-term durability of inflix ...... " in patients losing response.
@nl
P2093
P50
P1476
Long-term durability of inflix ...... n" in patients losing response
@en
P2093
Ana Gutierrez
Fernando Gomollón
Juan Luis Mendoza
Miguel Angel Montoro
Miriam Mañosa
Montserrat Andreu
Olga Merino
Valle García
P304
P356
10.1097/MCG.0B013E3181EBAEF9
P577
2011-02-01T00:00:00Z